Julia Barnes-Weise, JD
Ms. Julia Barnes-Weise is the founder and executive director of the Global Healthcare Innovation Alliance Accelerator. She has been a visiting associate professor of the practice at Duke’s Sanford School of Public Policy and director of the Innovation, Technology and Policy Project as well as a consultant and lecturer for the Duke Law School Access to Medicines course. Barnes-Weise is also a consultant to the WHO, the Coalition for Epidemic Preparedness and Innovation, and a frequent presenter at LES, LESI, AUTM and other conferences.
Barnes-Weise is a lawyer, entrepreneur and Certified Licensing Professional. She was formerly a director of business development at Glaxo Wellcome (now GSK), attorney at SAS Institute and has consulted for BioMatch LLC. Barnes-Weise has more than three decades of experience negotiating IP licenses, formulating alliance agreements and advising companies and institutions on partnering strategies.
She received a bachelor’s degree in economics and literature from Ohio Wesleyan University, a juris doctor degree from the University of North Carolina School of Law, completed a program in international trade from Notre Dame’s London Law Centre and studied international marketing through the Duke University and London Business School Joint International Marketing program.
Mark Currie, Ph.D.
Dr. Mark Currie earned a bachelor’s degree in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest University. He currently serves as Ironwood Pharmaceutical Inc.’s senior vice president of research and development and chief scientific officer. Previously, Dr. Currie initiated, built and led discovery pharmacology and served as director of arthritis and inflammation at Monsanto Company.
Deborah Geraghty, Ph.D
Dr. Geraghty brings 20 years of extensive experience in the life sciences industry, serving in senior strategic, commercial, and portfolio positions. Prior to Anokion, Deb was SVP, corporate strategy at Dimension Therapeutics, where she played a lead role in the company’s Series B financing and initial public offering, and was responsible for driving growth of the company’s portfolio prior to its successful IPO and recent acquisition by Ultragenyx Pharmaceutical Inc. Previous to Dimension, Dr. Geraghty was founder and vice president, project and portfolio development at Cydan Development, an orphan drug accelerator that raised $26 million to identify and de-risk assets with therapeutic and commercial potential. Prior, Dr. Geraghty was head of portfolio advancement at Aileron Therapeutics, where she led strategic growth and commercial efforts, and was director, new product marketing, at Infinity Pharmaceuticals. She also founded Back Bay Strategies, and held multiple positions at Kendall Strategies, Feinstein Kean Healthcare, and Genzyme Corp. Dr. Geraghty serves on the medical and scientific advisory board of Global Genes, a leading rare disease patient advocacy organization. She earned a BS in Biology at Union College, an MBA from the Carroll School at Boston College, and a PhD in Molecular Biology at the University of Vermont.
William Himmelsbach, MPH, FACHE
Mr. William Himmelsbach retired in 2012 as president and CEO of the Cardiovascular Research Foundation (CRF). CRF is a nonprofit academic research organization housing a pre-clinical lab, a clinical trials center and a medical education division and affiliated with Columbia University’s College of Physicians and Surgeons.
Prior to joining CRF, Himmelsbach was senior vice president at VHA and executive officer of its New York-based VHA Metro. VHA is a national healthcare alliance that provides supply chain management and clinical improvement service. Before that, he held president and CEO positions at several hospitals and healthcare systems, including the Institute of Living, Saint Mary’s Health Services, Holy Cross Health System and Detroit’s Receiving Hospital.
Himmelsbach is currently a guest lecturer in the MHA Program at MUSC. He remains on the board of CRF, chairs the board of directors at the Zucker Institute of Applied Neurosciences at MUSC and serves as vice chairman of the board of trustees of Beaufort Memorial Hospital. Himmelsbach holds a bachelor’s degree in labor-management relations and economics from Penn State University and a master’s degree in public health and healthcare administration from the University of Pittsburg. He is also a fellow of the American College of Healthcare Executives.
Joseph C. McDonald
Mr. Joseph McDonald is the president and CEO of Belimed Inc., a manufacturer of equipment for the medical and biopharmaceutical industries. Prior to his work at Belimed, McDonald was the president and COO of Berchtold Corporation and held a variety of senior management and leadership positions at Steris Corporation. He earned his business degree from Gannon University and completed executive business programs at both Columbia University and the University of Chicago.
Robert McQuade, Ph.D.
Dr. Robert D. McQuade is the executive vice president and chief strategic officer at Otsuka Pharmaceuticals Development and Commercialization. He joined Otsuka in 2004 and is responsible for guiding the strategic vision across its development profile and for its alliance partnerships.
McQuade has extensive experience in the pharmaceutical industry and across the discovery, development and positioning of new drugs, especially for the treatment of serious mental illnesses. Prior to Otsuka, he held a variety of positions at Bristol-Myers Squibb and at Schering-Plough. McQuade earned his bachelor’s degree from Davidson College and a Ph.D. in biochemistry from the University of North Carolina.
Perry B. Molinoff, M.D.
Dr. Perry Molinoff is a professor of pharmacology and the AN Richards professor of pharmacology emeritus at the University of Pennsylvania. He returned to a faculty position in the School of Medicine in 2007 after serving for three years as the vice provost for research at the University of Pennsylvania.
From 1981 through 1994, Molinoff was the AN Richards professor of pharmacology and the chairman of the department of pharmacology at the University of Pennsylvania. He earned his undergraduate and medical degrees from Harvard University and completed house officer’s training at the University of Chicago’s Hospitals and Clinics.
Arlene M. Morris
Ms. Morris was most recently the CEO and member of the board of directors for Syndax, an immuno-oncology and epigenetic drug development company in Boston. Previously, she was president and CEO of Affymax Inc., a biopharmaceutical company located in Palo Alto, which was spun out of GlaxoSmithKline (GSK) in 2001.
Prior to Affymax, Morris was president and CEO of Clearview Projects. Before that, she was the senior vice president of business development at both Coulter Pharmaceutical and Scios. Morris began her career at Johnson & Johnson (J&J), rising to vice president of business development. In addition to Syndax, she serves on the board of directors of Neovacs SA, Dimension Therapeutics, Palatin and Biodel. Morris recently served on the Humane Society of Silicon Valley and BIO board of directors as well. She received her bachelor’s degree in biology and chemistry from Carlow College.
Lita L. Nelsen
Lita Nelsen retired in 2016 from her position as Director of the Technology Licensing Office at the Massachusetts Institute of Technology, where she had been since 1986. She now works as a consultant in licensing, university technology transfer and entrepreneurship in the US, Europe and Asia.
Lita has served on many boards including the Association of University Technology as president. She was also on the board of Mass Ventures (MTDC) for 20 years, and is currently on the scientific advisory boards of Partners’ Investment Fund and the Massachusetts Life Sciences Center. The UK Government awarded her the honor of “Member of the Order of the British Empire” (MBE) for her work with technology transfer institutions throughout the UK.
Lita earned BS and MS degrees in Chemical Engineering from M.I.T. and an M.S. in Management (MBA) from M.I.T. as a Sloan Fellow. Prior to joining the M.I.T. TLO, she spent 20 years in industry, primarily in the fields of membrane separations, medical devices, and biotechnology.
Art Pappas, MBA
Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life science companies. Art founded Pappas Capital in 1994, and over the past twenty-four years the firm has managed more than $540 million in capital and invested in more than 75 life science companies through its flagship Pappas Ventures business unit, as well as its Specialized Fund Management business unit.
Art currently serves as a director for Arix Bioscience, Aura Biosciences and OrphoMed, and as a board observer for Amplyx Pharmaceuticals, Balance Therapeutics, CuraSen Therapeutics and Real Endpoints. Prior to founding Pappas Capital, Art held senior level leadership positions at several multinational pharmaceutical companies for which he was responsible for the development, licensing and launch of a number of global products. He was an executive member of the board of directors of Glaxo Holdings plc (NYSE: GLX, now GSK), and served as Glaxo’s chief executive responsible for international operations including research, development and manufacturing. Prior to Glaxo, Art was Vice President of Commercial Operations for Abbott International, and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. He previously served as Chairman and founding CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD) (acquired by Eli Lilly in 2017), and on the boards of Afferent Pharmaceuticals (acquired by Merck in 2016), Chimerix (NASDAQ: CMRX), Quintiles Transnational Corp. (NASDAQ: QTRN, now NASDAQ: IQV), TYRX (acquired by Medtronic in 2013), Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics (acquired by BioMarin in 2010), CardioDx, and Embrex (NASDAQ: EMBX) (acquired by Pfizer in 2006). He also served as a board observer for Kezar Life Sciences (NASDAQ: KZR) and Plexxikon (acquired by Daiichi Sankyo in 2011).
Art is a member of the Board of Directors of the North Carolina Biotechnology Center, where he is a past chair, and the Medical University of South Carolina Foundation for Research Development. He is a member of the Board of Trustees of The Wistar Institute (a National Cancer Institute center), the Board of Advisors of the Duke Cancer Institute, and the Advisory Board of the BioExec Institute. He is also a member of the CEO Roundtable on Cancer and BayHelix, an organization of global life science community leaders. He previously served on the Board of Directors of the National Venture Capital Association. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center. Art received a BS in biology from The Ohio State University and an MBA in finance from Xavier University.
Paul Williamson, M.D.
Dr. Paul Williamson earned his bachelor’s and master’s degrees from the University of Massachusetts. He completed a medical residency at the St. Vincent Hospital in Worcester and a rheumatology fellowship at the Hospital of the University of Pennsylvania in Philadelphia. Williamson is a board-certified internist and rheumatologist. In addition to practicing rheumatology in Massachusetts, he was the chief of medicine at the Union Hospital Campus of the North Shore Medical Center, the medical director of the North Shore Medical Group Inc., a member of the executive committee of Charter Professional Services Corporation, a subsidiary of Partners HealthCare System, and a member of Partners HealthCare Chiefs’ council.
Williamson joined the Johnson & Johnson Family of Companies in 2001 and left in 2014 to individually pursue the development of and investment in early stage technologies to satisfy unmet medical needs. He currently serves on the advisory board of the Innovation Support Center of Harrington Discovery Institute, where he advises university-based physician scientists on accelerating the development of their inventions toward commercialization. In addition, Williamson is actively involved with Charleston Angel Partners as an investor in early stage technologies within the life sciences.
MUSC Appointed Members
William (Bill) A. Baker Jr., DHL (Hon.)
Mr. Baker began his term on the MUSC board of trustees in 2014, as the Governor’s at-large appointee. He is chairman of the board of The Baker Companies, a residential and industrial real estate development and investment company headquartered in White Plains, New York, with operations in New York, New Jersey, Connecticut, Pennsylvania, Delaware and North Carolina. An active volunteer with hospitals, Baker was vice chair of Northern Westchester Center and a founding member of Stellaris Health Network. He was on the board of Georgetown University where he chaired the committee on medical center affairs.
Locally, Baker served as vice chair of the MUSC Foundation. He was awarded an honorary doctorate degree by MUSC in 2008. Currently, Baker serves as chairman of the Horizon Project Foundation board. He is a graduate of Georgetown University and the Harvard Business School.
Kathleen T. Brady, M.D., Ph.D.
Dr. Brady is a board-certified psychiatrist, distinguished university professor, and vice president for research and director of the South Carolina Clinical & Translational Research (SCTR) Institute at the Medical University of South Carolina. Her research focuses on substance use and posttraumatic stress disorder, with an emphasis on translating study findings into effective treatment interventions. Dr. Brady has authored more than 350 publications, is a world-class lecturer and has received several meritorious awards for her dedication.
Nancy DeMore, M.D., FACS
Dr. DeMore is a surgical oncologist with 20 years of experience in tumor angiogenesis and translational research. She received her training in general surgery at Boston University, during which she did a three-year surgical research fellowship under the mentorship of Dr. Judah Folkman at Harvard Medical School.
After completing her general surgery residency, Dr. DeMore trained at Memorial Sloan-Kettering Cancer Center for a fellowship in Surgical Oncology from 1999-2001. She was professor of surgery at the University of North Carolina at Chapel Hill from 2001-2014, where her clinical practice focused on breast surgical oncology, and was PI or co-investigator on 30 clinical trials. The NIH has funded Dr. DeMore since 2001, and her research program has focused on the discovery of novel angiogenesis targets and subsequent drug development. She currently serves on the NIH Cancer Immunopathology and Immunotherapy Study Section.
Dr. DeMore is presently professor and interim chief of surgical oncology, medical director of the MUSC Breast Center, BMW-endowed chair in cancer research, and vice chair of entrepreneurship at MUSC. She is also co-founder and chief scientific officer of Enci Therapeutics, a biotech start-up company.
Jesse Goodwin, Ph.D.
Dr. Goodwin is the Chief Innovation Officer for the Medical University of South Carolina. Prior to this role, Dr. Goodwin was the Vice President of Development for the Zucker Institute for Applied Neurosciences (ZIAN), a technology accelerator serving the Neurosciences at MUSC and had also served as the Deputy Director of the MUSC Foundation for Research Development (FRD). In these capacities, she effectuates the translation of university innovations into products and services that improve health and patient care through her ability to strategically plan across multiple aspects of an innovation pipeline and to earn the trust of stakeholders necessary to coalesce support and build collaborations.
Dr. Goodwin came to MUSC from a Boston-based intellectual property (IP) consulting firm where she was Director of the Medical Device division, providing insight to client companies on IP matters pertaining to a vast array of medical technologies. Dr. Goodwin completed a post-doctoral fellowship in the Harvard-MIT Health Sciences and Technology program. She holds a Ph.D. in Biomedical Engineering from Stony Brook University.
Kenneth Ruggiero, Ph.D.
Dr. Ruggiero is professor and co-director of the Technology Applications Center for Healthful Lifestyles (TACHL), as well as director of the Telehealth Resilience and Recovery Program. He received his bachelor’s degree in psychology from the State University of New York at Buffalo and master’s degree and Ph.D. in clinical psychology from West Virginia University. He completed his internship and NIH-funded postdoctoral fellowship at MUSC.
Dr. Ruggiero's work centers on the development, evaluation, and dissemination of technology-based interventions to improve population mental health. This includes research on brief, self-help interventions for disaster victims as well as stepped care approaches for survivors of traumatic injury. A second major line of his work aims to improve quality of care in community mental health service settings through the development of scalable, technology-enhanced activities for providers. Dr. Ruggiero has had continuous extramural funding from the National Institutes of Health since 2001.
As principal investigator, he has led more than a dozen grants funded by NIH, VA and Department of Homeland Securities, and has served as co-investigator on numerous grants funded by DoD, NIDA, and SAMHSA. Dr. Ruggiero has more than 150 scholarly publications and 180 presentations, and has served as a formal mentor to dozens of trainees and faculty members. He is a standing member of an NIH review panel and serves on four editorial boards.
Lisa K. Saladin, PT, Ph.D., FAPTA
Dr. Lisa Saladin is currently the Executive Vice President for Academic Affairs and Provost at the Medical University of South Carolina (MUSC). In this capacity, she serves as the chief academic officer of the university with administrative oversight and leadership over all six colleges (Medicine, Dental Medicine, Pharmacy, Nursing, Health Professions, and Graduate Studies), Hollings Cancer Center, the Offices of Research, Education and Student Life, Gender Equity, and the MUSC Library. She manages a total budget of approximately 40 million dollars and supervises 18 direct reports. Prior to serving in this role, Dr. Saladin was Dean of the College of Health Professions at MUSC where she has been a faculty member for the last 27 years. As Dean, she led a faculty and staff of nearly 140 individuals, directed a budget of approximately 34 million dollars, and provided oversight of nine academic programs. Dr. Saladin earned a Bachelor of Medical Rehabilitation (Physical Therapy) and a Master of Science in Anatomy (Neuroscience) from the University of Manitoba in Canada and a Doctor of Philosophy in Physical Therapy from Nova Southeastern University in Florida.
Dr. Saladin’s clinical expertise is physical therapy for individuals with neurological disorders, and her research interests are racial and gender disparities in access to care, community-based service learning, and motor control and treatment outcomes for individuals with neurological disorders. Dr. Saladin is best known for her excellence as an educator. She has experience in curriculum development, inter-professional education, distance education, and development of innovative methods to engage and motivate students to learn. She has been widely recognized for her teaching excellence with three University Health Sciences Teaching Excellence Awards, a South Carolina Governor’s Distinguished Professor Award, and a 2009 MUSC Master Teacher designation. In 2008, she was recognized nationally for her teaching excellence by the American Physical Therapy Association (APTA) and received the Award for Excellence in Academic Teaching.
Dr. Saladin serves on the board of the MUSC Foundation for Research Development; as Vice-President and a board member of the American Physical Therapy Association; and as Chair of the APTA Public Policy and Advocacy Committee. As Chair of this committee, she receives monthly updates on national healthcare policy issues and is actively engaged in payment reform, new healthcare delivery models, telehealth, and legislative advocacy. She meets regularly with legislators and policy makers in DC and has been invited to make national presentations on healthcare reform and the future of healthcare.
A lifetime resident of Charleston, Mr. Stavrinakis was elected to the MUSC board of trustees in 2013 as a lay representative from the First Congressional District. He is president, founder and CEO of Manny’s Grills, Cafe’s and Franchise Group, operating five units in three states.
He graduated from Charleston Southern University in 1986 with a bachelor’s degree in economics and is a lifetime member of the Holy Trinity Greek Orthodox church. He served on the Charleston Aviation Authority and was chairman of the Committee on Human Resources. He is a platinum member of the Charleston Chamber of Commerce and a member of the Navy League of the University States.
Michael Yost, Ph.D.
Dr. Michael Yost is the associate chairman for research at MUSC and director of research for general surgery, trauma and critical care surgery. He is responsible for all facets of the research effort in the department of surgery, division of general surgery and acute care including recruitment, personnel management, budget management and control, scientific direction, funding procurement and intellectual property.
Dr. Yost has significant startup and industrial experience. He was the vice chairman of Vitasol LLC, a biotech startup company that specializes in novel resuscitative fluids and strategies. Dr. Yost also spent more than 15 years as a research and process engineering manager. He has more than 70 publications and 13 patents and patent applications in the areas of tissue engineering and resuscitation.
Ex Officio Member
Lawrence S. Olanoff, M.D., Ph.D.
Dr. Larry Olanoff is special advisor to the president for corporate relations at MUSC. After a long career in the pharmaceutical industry, he retired from his last position as president and COO at Forest Laboratories Inc., and served as a director of Forest Laboratories Inc. until 2014. Dr. Olanoff was president and CEO of Celsion Corporation from 2005 to 2006. From 1995 until 2005, he was the executive vice president of scientific affairs for Forest Laboratories. From 1993 to 1995, Dr. Olanoff was the senior vice president of clinical research and development at Sandoz Pharmaceutical Corporation. From 1984 to 1993, he was employed by the Upjohn Company, where his last position was corporate vice president of clinical development and medical affairs.
Dr. Olanoff holds a master’s degree and Ph.D. in biomedical engineering from Case Western Reserve University and was a medical resident and clinical pharmacology fellow at MUSC. He is board-certified in clinical pharmacology and is the author or co-author of numerous scientific publications in the fields of clinical pharmacology, drug delivery and pharmacokinetics. Dr. Olanoff currently serves as an advisor to the Harrington Discovery Institute (HDI) Innovation Support Center and is a member of the scientific advisory board of BioMotiv, the for-profit partner to the HDI. He is a board member of Ironwood Pharmaceuticals and Axovant Sciences Ltd., as well as several local nonprofit organizations serving biomedical research. Dr. Olanoff is the founder of the Technology Accelerator Company, a nonprofit organization that supports biomedical research innovations in SC.
Daniel D. Adams, JD
Mr. Daniel Adams is the executive chairman of Protein Sciences Corporation. He previously founded and managed Advanced Genetic Sciences Inc., Biogen Idec, AlleRx and Plant Genetic Systems. Adams holds a bachelor’s degree in chemistry from Cornell University and a juris doctor degree magna cum laude from New York University School of Law.
Harold E. Chappelear, LLD (Hon.)
Dr. Harold Chappelear holds a bachelor’s degree in pharmacy from the Medical University of South Carolina (now South Carolina College of Pharmacy, MUSC Campus) and a doctor of laws degree from the University of Maryland. Additionally, he completed postgraduate work in psychology and economics at Jacksonville University and the University of Florida.
After participating in the private practice of pharmacy, Dr. Chappelear joined the Upjohn Company in 1962 and retired in 1992 as a corporate executive vice president. In 1992, he joined Medicis Pharmaceutical Corporation serving as president, COO, and a member of the board of directors until 1995. He is now vice chairman of UPM Pharmaceuticals Inc. and is also a principal of Quintel International.
Carl Ehmann, M.D.
Dr. Carl Ehmann received a bachelor’s degree and a master’s degree from State University of New York at Buffalo. He has held academic appointments at the University of Pennsylvania, Wake Forest University, New York University and the University of Minnesota.
Dr. Ehmann is a former chairman of the FRD board of directors. During his career, he was the research and development leader of several large multi-national companies including Bristol-Myers (Dermatology), Johnson & Johnson Consumer Products Company, Reynolds Technology Inc. and Reckitt & Coleman. Dr. Ehmann began his industrial research career at Hoffmann-LaRoche Pharmaceutical Company.
Layton McCurdy, M.D.
Dr. Layton McCurdy served as president of the American Board of Psychiatry and Neurology from 1990 to 1991, president of the American College of Psychiatrists from 1993 to 1994, and president of the Association of Chairmen of Departments of Psychiatry from 1979 to 1980.
McCurdy currently serves as a member of the board of advisors at CureSource Inc. He has participated in national advisory positions for the Department of Veterans Affairs and for the National Institute of Mental Health (NIMH), where he was a presidential appointee to the NIMH Advisory Council from 1978 to 1982. McCurdy is dean emeritus and professor of Psychiatry and Behavioral Sciences at MUSC.